View Older Stories View More Recent Stories
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
-
CFRA Upgrades Eli Lilly (LLY) to Buy (earlier)
-
Lilly opens new Gateway Labs facility in San Diego
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Lilly to build $6.5 billion manufacturing facility in Houston
-
UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
-
Eli Lilly partners with Prellis Biologics on antibody drug discovery
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
Trump: tariffs will get countries to agree to drug pricing plan
-
BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY), full ATTAIN-1 data 'broadly positive'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY)
-
Berenberg Downgrades Eli Lilly (LLY) to Hold
-
FDA issues warning letter to Eli Lilly over ZEPBOUND promotional video
-
FDA warns Eli Lilly over misleading weight-loss drug promotion
-
Eli Lilly plans $5 billion Virginia manufacturing facility
-
How are GLP-1 drugs changing U.S. grocery behavior?
-
Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Eli Lilly launches AI platform for biotech drug discovery
-
Lilly's Jaypirca shows improved survival in treatment-naive CLL study
-
FDA grants breakthrough therapy status to Lilly's lung cancer drug olomorasib
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
BMO Capital: 'Eli Lilly (LLY) Shares Expected to Trade Higher Post ATTAIN-1 Data'
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Lilly's Verzenio shows survival benefit in breast cancer trial
-
HSBC Upgrades Eli Lilly (LLY) to Hold
-
TD Cowen on Eli Lilly (LLY): 'Orfo Successful In ATTAIN-2, Regulatory Submission Underway; Model Updated'
-
William Blair on Orforglipron: 'It is therefore our opinion that orforglipron could be seamlessly incorporated into patients’ daily routines'
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY), 'early innings in obesity still'
-
Immuneering secures clinical supply deal with Lilly for cancer drug combo
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
-
Mizuho: Viking (VKTX) Oral Obesity Program is 'Quite Discouraging'
-
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs
-
Eli Lilly (LLY) PT Lowered to $825 at Cantor Fitzgerald
